SG11202011355QA - Optimized gp41-binding molecules and uses thereof - Google Patents

Optimized gp41-binding molecules and uses thereof

Info

Publication number
SG11202011355QA
SG11202011355QA SG11202011355QA SG11202011355QA SG11202011355QA SG 11202011355Q A SG11202011355Q A SG 11202011355QA SG 11202011355Q A SG11202011355Q A SG 11202011355QA SG 11202011355Q A SG11202011355Q A SG 11202011355QA SG 11202011355Q A SG11202011355Q A SG 11202011355QA
Authority
SG
Singapore
Prior art keywords
optimized
binding molecules
molecules
binding
Prior art date
Application number
SG11202011355QA
Inventor
Chia-Ying Lam
Gundo Diedrich
Jeffrey Nordstrom
Liqin Liu
Leslie Johnson
Scott Koenig
Barton Haynes
Guido Ferrari
Original Assignee
Macrogenics Inc
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc, Univ Duke filed Critical Macrogenics Inc
Publication of SG11202011355QA publication Critical patent/SG11202011355QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
SG11202011355QA 2018-05-18 2019-05-13 Optimized gp41-binding molecules and uses thereof SG11202011355QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862673462P 2018-05-18 2018-05-18
PCT/US2019/032030 WO2019222104A1 (en) 2018-05-18 2019-05-13 Optimized gp41-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
SG11202011355QA true SG11202011355QA (en) 2020-12-30

Family

ID=68540936

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011355QA SG11202011355QA (en) 2018-05-18 2019-05-13 Optimized gp41-binding molecules and uses thereof

Country Status (12)

Country Link
US (1) US20210246194A1 (en)
EP (1) EP3794027A4 (en)
JP (1) JP2021524451A (en)
CN (1) CN112533945A (en)
AU (1) AU2019269383A1 (en)
BR (1) BR112020023432A2 (en)
CA (1) CA3100398A1 (en)
IL (1) IL278832A (en)
MX (1) MX2020012309A (en)
SG (1) SG11202011355QA (en)
WO (1) WO2019222104A1 (en)
ZA (1) ZA202007056B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106573050B (en) 2014-05-29 2021-09-24 宏观基因有限公司 Trispecific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
ES2935062T3 (en) * 2014-09-26 2023-03-01 Macrogenics Inc Bispecific monovalent diabodies that are capable of binding CD19 and CD3 and uses thereof
KR20200098590A (en) 2017-12-12 2020-08-20 마크로제닉스, 인크. Bispecific CD16-binding molecule and its use in disease treatment
CN111647078B (en) * 2020-06-22 2022-04-26 中国医学科学院医学生物学研究所 anti-HIV monoclonal antibody and preparation method and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0816785A2 (en) * 2007-09-14 2017-05-02 Adimab Inc rationally designed synthetic antibody libraries, and uses thereof
US9908938B2 (en) * 2013-03-14 2018-03-06 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
WO2015013390A1 (en) * 2013-07-25 2015-01-29 Pincus Seth Anti-hiv dual specificity antibodies and methods of hiv treatment
UA116479C2 (en) * 2013-08-09 2018-03-26 Макродженікс, Інк. Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
CN106573050B (en) * 2014-05-29 2021-09-24 宏观基因有限公司 Trispecific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
JP6932639B2 (en) * 2014-09-29 2021-09-08 デューク ユニバーシティ Bispecific molecule with HIV-1 envelope targeting arm
JP6811723B2 (en) * 2015-04-17 2021-01-13 アイジーエム バイオサイエンシズ インコーポレイテッド Multivalent human immunodeficiency virus antigen-binding molecule and its usage
EP3359569A2 (en) * 2015-10-06 2018-08-15 Alector LLC Anti-trem2 antibodies and methods of use thereof
US20200255524A1 (en) * 2016-06-07 2020-08-13 Macrogenics, Inc. Combination therapy

Also Published As

Publication number Publication date
CA3100398A1 (en) 2019-11-21
AU2019269383A1 (en) 2020-12-10
ZA202007056B (en) 2021-10-27
EP3794027A1 (en) 2021-03-24
CN112533945A (en) 2021-03-19
US20210246194A1 (en) 2021-08-12
WO2019222104A1 (en) 2019-11-21
JP2021524451A (en) 2021-09-13
EP3794027A4 (en) 2022-02-09
BR112020023432A2 (en) 2021-02-23
IL278832A (en) 2021-01-31
MX2020012309A (en) 2021-06-08

Similar Documents

Publication Publication Date Title
IL269534A (en) Chimeric molecules and uses thereof
ZA201905905B (en) Anti-gprc5d antibody and molecule comprising the antibody
IL267942B (en) Anti-cd73 antibodies and uses thereof
ZA202001113B (en) Anti-cd137 molecules and use thereof
IL268734A (en) Anti-lag-3 antibodies and uses thereof
IL268700A (en) Anti-phf-tau antibodies and uses thereof
EP3331549A4 (en) Improved microbe-binding molecules and uses thereof
IL271477A (en) Anti-cd166 antibodies and uses thereof
IL293377B1 (en) Hsd17b13 variants and uses thereof
IL269134A (en) Anti-par2 antibodies and uses thereof
HK1248721A1 (en) Antibody molecules and uses thereof
EP3511407A4 (en) Christensenella intestinihominis and application thereof
ZA201806597B (en) Ilt7 binding molecules and methods of using the same
EP4076448A4 (en) Fluoroalkyl-oxadiazoles and uses thereof
SG10201912366YA (en) Anti-cd3 antibody and molecules comprising the antibody
IL278832A (en) Optimized gp41-binding molecules and uses thereof
IL272476A (en) Anti-apelin antibodies and uses thereof
IL273157A (en) Axl-specific antibodies and uses thereof
IL271398A (en) Anti-l1-cam antibodies and uses thereof
SG11202006459XA (en) Proteinaceous molecules and uses therefor
GB201712032D0 (en) Antibodies and uses thereof
IL284781A (en) Lilrb3-binding molecules and uses therefor
IL280369A (en) New myokines and uses thereof
IL285585A (en) Fcmr-binding molecules and uses thereof
EP4081255A4 (en) Anti-csf1r molecules and use thereof